RT Journal Article
SR Electronic
T1 JOINT CONTRIBUTION OF MARKERS OF NEURODEGENERATION AND HYPERCHOLESTEROLEMIA TO DEMENTIA RISK
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.16.22269370
DO 10.1101/2022.01.16.22269370
A1 Laura Perna
A1 Ute Mons
A1 Hannah Stocker
A1 Léon Beyer
A1 Konrad Beyreuther
A1 Kira Trares
A1 Bernd Holleczek
A1 Ben Schöttker
A1 Robert Perneczky
A1 Klaus Gerwert
A1 Hermann Brenner
YR 2022
UL http://medrxiv.org/content/early/2022/01/16/2022.01.16.22269370.abstract
AB Background The examination of markers of neurodegeneration (glial fibrillary acidic protein; GFAP, neurofilament light chain; NfL, phosphorylated tau181; p-tau181) among individuals with high comorbidity of neurodegenerative and cerebrovascular disease and their interplay with vascular risk factors, particularly high cholesterol levels, might contribute to explaining the link between body and brain. The aim of this study was to assess whether the association of GFAP, NfL, and p-tau181 with dementia risk varies depending on levels of total cholesterol (TC) and APOE ε4 genotype.Methods Nested case-control study embedded within a population-based cohort and including 768 older adults (261 dementia cases and 508 randomly selected controls) followed for up to 17 years with regard to clinical diagnosis of various age-related diseases. GFAP, NfL, and p-tau181 were measured in baseline blood samples using the Single-Molecule Array (Simoa) Technology (Quanterix, USA) and categorized into high (quartile 4) versus low (quartiles 1-3). Logistic regression analyses and spline regression models for dose-response analyses were used. ROC curves by cholesterol levels were also calculated.Results The risk of a dementia diagnosis was significantly increased between participants with high vs. low levels of GFAP and NfL and the risk substantially varied by TC levels. For GFAP and NfL the ORs of a dementia diagnosis were 5.10 (2.45-10.60) and 2.96 (1.43-6.14) in participants with high and 2.44 (1.47-4.07) and 1.15 (0.69-1.92) in those with low TC. APOE ε4 genotype further modified the strength of the associations with different patterns, depending on specific marker and type of dementia. No significant association was seen with p-tau181.Conclusions These results suggest that in the general population blood GFAP and NfL are better predictors of dementia than p-tau181 and that their associations with dementia risk are highly amplified by hypercholesterolemia, also depending on APOE ε4 genotype.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe ESTHER study was funded by grants from the Saarland State Ministry for Social Affairs, Health, Women and Family Affairs (Saarbruecken, Germany), the Baden-Wuerttemberg State Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany) and the Federal Ministry of Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany). UM is supported by the Marga and Walter Boll Foundation, Kerpen, Germany. None of the funding sources had a role in the conduct of the study, in the analysis or interpretation of the data, in the writing of this manuscript or in the decision to submit it for publication. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ESTHER study was approved by the Ethics Committee of the Medical Faculty at Heidelberg University and the Physicians' Board of Saarland.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to restrictions of informed consent of the ESTHER study, we are not allowed making the dataset publicly available. However, all data produced in the present study are available upon reasonable request to the authors.